The
Compared with standard intravenous (IV) delivery,
Having previously been administered via IV infusion, which takes approximately 30-60 minutes, the new subcutaneous injection means administration takes approximately seven minutes, with the average injection only taking between four and eight minutes, based on data presented at ESMO 2023.
Roche’s Tecentriq SC (atezolizumab)
Tecentriq binds to the programmed death ligand-1 (PD-L1) protein and blocks its interactions with both PD-1 and B7.1 receptors. Through its inhibition of PD-L1, Tecentriq may facilitate T-cell activation,
CHMP recommends new immunotherapy delivery method
Fundamentally, this administration approach "provides more flexibility to patients, while also helping to free up resources in constrained healthcare systems," Dr
The company also highlighted that the intravenous (IV) infusion of Tecentriq was the first cancer immunotherapy approved for certain early-stage (adjuvant) NSCLCs, small cell lung cancer (SCLC) and hepatocellular carcinoma (HCC).
What led to the marketing approval
The marketing authorisation from the EC for this indication is based on pivotal data from the Phase IB/III IMscin001 study. This study evaluated patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), who had experienced previous failed platinum therapy.
The findings showed comparable levels of Tecentriq in the blood, when administered subcutaneously, and that this formulation held a safety and efficacy profile consistent with the intravenous (IV) formulation, according to
Additionally, the overall response and survival rates, as well as progression-free survival and duration of response, were found to be similar between the subcutaneously and intravenously-treated patients.
"The availability of a subcutaneous cancer immunotherapy option that can… allow for treatment outside of a hospital will undoubtedly make a significant difference to patients and their loved ones," Dr
Clinical trial-first for liver cancer immunotherapy combo
The post
© Russell Publishing Limited, 2024. All Rights Reserved., source